ストックスクリーナーアプリを入手
1.93
7.22%
0.13
プレマーケット:
1.96
0.03
+1.55%
前日終値:
$1.80
開ける：
$1.78
24時間の取引高:
902.25K
Relative Volume:
0.68
時価総額：
$133.50M
収益：
-
当期純損益:
$-89.66M
株価収益率:
-0.7974
EPS:
-2.4205
ネットキャッシュフロー:
$-81.90M
1週間 パフォーマンス:
+22.15%
1か月 パフォーマンス:
+11.56%
6か月 パフォーマンス:
-57.49%
1年 パフォーマンス:
+34.03%
1日の値動き範囲:
$1.73
$1.93
1週間の範囲:
$1.52
$1.93
52週間の値動き範囲:
$1.01
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Compare PEPG vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.93 | 124.50M | 0 | -89.66M | -81.90M | -2.4205 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-09 | 開始されました | Guggenheim | Buy |
| 2024-12-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-07-31 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-21 | 開始されました | H.C. Wainwright | Buy |
Pepgen Inc (PEPG) 最新ニュース
Pictet Asset Management Holding SA Purchases 871,059 Shares of PepGen, Inc. $PEPG - MarketBeat
Stifel reiterates Buy on PepGen stock amid partial clinical hold - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - ChartMill
PepGen crashes after mid-stage trial data for muscle disorder therapy - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - FinancialContent
[ARS] PepGen Inc. SEC Filing - Stock Titan
PepGen (NASDAQ: PEPG) details 2026 virtual meeting and auditor vote - Stock Titan
PepGen advances momentum with Palo Alto meeting on DM1 community engagement - Traders Union
PepGen shares slide 20% as FDA clinical hold overshadows earnings beat - MSN
Wedbush Maintains PepGen (PEPG) Outperform Recommendation - MSN
PepGen Inc. tops EPS estimates by 29.3%, narrower loss no revenueReal Trader Insights - Cổng thông tin điện tử tỉnh Lào Cai
PepGen’s stock up 120% on DM1 trial success - MSN
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
PEPG Stock Price, Quote & Chart | PEPGEN INC (NASDAQ:PEPG) - ChartMill
PepGen (PEPG) Stock: Sentiment Overview (Bearish Sentiment) 2026-04-16Attention Driven Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
PEPG News | PEPGEN INC (NASDAQ:PEPG) - ChartMill
Biotech Firm PepGen Receives 'Moderate Buy' Rating from Analysts - National Today
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PepGen: Modest FREEDOM2 Efficacy, Regulatory Overhang, and Competitive Pressures Underscore Sell Rating - TipRanks
Signal Recap: Should I set a stop loss on PepGen Inc2026 Pullback Review & Technical Confirmation Alerts - baoquankhu1.vn
PepGen team joins Kansas City event to drive myotonic dystrophy research discussions - Traders Union
Rate Cut: Does PepGen Inc have declining or rising EPSAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
PepGen joins MyotonicStrong conference to present clinical progress - Traders Union
Top 3 Health Care Stocks Which Could Blast Off This Quarter - Benzinga
PEPG Q4 2025 Earnings: PepGen Inc. Beats EPS Estimates, No Revenue PostedHot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Retail Trends: Is PepGen Inc forming a breakout pattern2026 Chart Watch & Long Hold Capital Preservation Tips - baoquankhu1.vn
Published on: 2026-04-07 21:04:49 - baoquankhu1.vn
PEPG.O Technical Analysis & Stock Price Forecast - Intellectia AI
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
PEPG Technical Analysis & Stock Price Forecast - Intellectia AI
PepGen stock plunges 26% on FDA partial clinical hold - Investing.com
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway - National Today
Biopharma bites: PepGen's partial pause, Roche's Korea investment, plus Teva's financing - FirstWord Pharma
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Assay what? Eyes on Pepgen’s vim-sapping DM1 phase II - BioWorld MedTech
Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts - TipRanks
PEPG: FREEDOM2's 5 mg/kg cohort showed promising safety and efficacy, supporting dose escalation - TradingView — Track All Markets
MACD Signal: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEAR2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
Pepgen Inc (PEPG) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):